Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Choroidal neovascularization in an adolescent with RDH12-associated retinal degeneration.

Philip S, Xu X, Laud KG, Sengillo JD, Tsang SH, Yannuzzi LA.

Ophthalmic Genet. 2019 Aug;40(4):362-364. doi: 10.1080/13816810.2019.1655770. Epub 2019 Aug 19.

PMID:
31424981
2.

Systems biology of Ewing sarcoma: a network model of EWS-FLI1 effect on proliferation and apoptosis.

Stoll G, Surdez D, Tirode F, Laud K, Barillot E, Zinovyev A, Delattre O.

Nucleic Acids Res. 2013 Oct;41(19):8853-71. doi: 10.1093/nar/gkt678. Epub 2013 Aug 8.

3.

Outer retinal tubulation in degenerative retinal disorders.

Goldberg NR, Greenberg JP, Laud K, Tsang S, Freund KB.

Retina. 2013 Oct;33(9):1871-6. doi: 10.1097/IAE.0b013e318296b12f.

4.

Double peeling during vitrectomy for macular pucker: the Charles L. Schepens Lecture.

Chang S, Gregory-Roberts EM, Park S, Laud K, Smith SD, Hoang QV.

JAMA Ophthalmol. 2013 Apr;131(4):525-30. doi: 10.1001/jamaophthalmol.2013.2176.

PMID:
23579603
5.

Oncostatin M is a growth factor for Ewing sarcoma.

David E, Tirode F, Baud'huin M, Guihard P, Laud K, Delattre O, Heymann MF, Heymann D, Redini F, Blanchard F.

Am J Pathol. 2012 Nov;181(5):1782-95. doi: 10.1016/j.ajpath.2012.07.023. Epub 2012 Sep 13.

PMID:
22982441
6.

Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma.

Postel-Vinay S, Véron AS, Tirode F, Pierron G, Reynaud S, Kovar H, Oberlin O, Lapouble E, Ballet S, Lucchesi C, Kontny U, González-Neira A, Picci P, Alonso J, Patino-Garcia A, de Paillerets BB, Laud K, Dina C, Froguel P, Clavel-Chapelon F, Doz F, Michon J, Chanock SJ, Thomas G, Cox DG, Delattre O.

Nat Genet. 2012 Feb 12;44(3):323-7. doi: 10.1038/ng.1085.

PMID:
22327514
7.

Acquired vitelliform lesion associated with large drusen.

Lima LH, Laud K, Freund KB, Yannuzzi LA, Spaide RF.

Retina. 2012 Apr;32(4):647-51. doi: 10.1097/IAE.0b013e31823fb847.

PMID:
22218150
8.

Acquired Vitelliform Lesions: correlation of clinical findings and multiple imaging analyses.

Freund KB, Laud K, Lima LH, Spaide RF, Zweifel S, Yannuzzi LA.

Retina. 2011 Jan;31(1):13-25. doi: 10.1097/IAE.0b013e3181ea48ba.

PMID:
21102371
9.

Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients.

Odri GA, Dumoucel S, Picarda G, Battaglia S, Lamoureux F, Corradini N, Rousseau J, Tirode F, Laud K, Delattre O, Gouin F, Heymann D, Redini F.

Cancer Res. 2010 Oct 1;70(19):7610-9. doi: 10.1158/0008-5472.CAN-09-4272. Epub 2010 Sep 14.

10.

EWS-FLI1 inhibits TNFalpha-induced NFkappaB-dependent transcription in Ewing sarcoma cells.

Lagirand-Cantaloube J, Laud K, Lilienbaum A, Tirode F, Delattre O, Auclair C, Kryszke MH.

Biochem Biophys Res Commun. 2010 Sep 3;399(4):705-10. doi: 10.1016/j.bbrc.2010.08.004. Epub 2010 Aug 5.

PMID:
20691659
11.

Ophthalmomyiasis with a singular subretinal track.

Lima LH, Laud K, Rosenberg P, Tuller R, Olsen K, Yannuzzzi LA.

Am J Ophthalmol. 2010 Nov;150(5):731-736.e1. doi: 10.1016/j.ajo.2010.05.032. Epub 2010 Aug 5.

PMID:
20688311
12.

Choroidal macrovessel.

Lima LH, Laud K, Chang LK, Yannuzzi LA.

Br J Ophthalmol. 2011 Sep;95(9):1333-4. doi: 10.1136/bjo.2009.176800. Epub 2010 Aug 3. No abstract available.

PMID:
20682950
13.

Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival.

Picarda G, Lamoureux F, Geffroy L, Delepine P, Montier T, Laud K, Tirode F, Delattre O, Heymann D, Rédini F.

Clin Cancer Res. 2010 Apr 15;16(8):2363-74. doi: 10.1158/1078-0432.CCR-09-1779. Epub 2010 Apr 6.

14.

Outer retinal tubulation: a novel optical coherence tomography finding.

Zweifel SA, Engelbert M, Laud K, Margolis R, Spaide RF, Freund KB.

Arch Ophthalmol. 2009 Dec;127(12):1596-602. doi: 10.1001/archophthalmol.2009.326. Erratum in: Arch Ophthalmol. 2012 Jul 1;130(7):856.

PMID:
20008714
15.

Protective effect of copy number polymorphism of glutathione S-transferase T1 gene on melanoma risk in presence of CDKN2A mutations, MC1R variants and host-related phenotypes.

Chaudru V, Lo MT, Lesueur F, Marian C, Mohamdi H, Laud K, Barrois M, Chompret A, Avril MF, Demenais F, Bressac-de Paillerets B.

Fam Cancer. 2009;8(4):371-7. doi: 10.1007/s10689-009-9249-5. Epub 2009 May 31.

PMID:
19484507
16.

Alteration of cyclin D1 transcript elongation by a mutated transcription factor up-regulates the oncogenic D1b splice isoform in cancer.

Sanchez G, Bittencourt D, Laud K, Barbier J, Delattre O, Auboeuf D, Dutertre M.

Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):6004-9. doi: 10.1073/pnas.0710748105. Epub 2008 Apr 14.

17.

Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation.

Freund KB, Ho IV, Barbazetto IA, Koizumi H, Laud K, Ferrara D, Matsumoto Y, Sorenson JA, Yannuzzi L.

Retina. 2008 Feb;28(2):201-11. doi: 10.1097/IAE.0b013e3181669504.

PMID:
18301024
18.

Optic nerve macroaneurysms as the initial presentation of idiopathic retinal vasculitis, aneurysms, and neuroretinitis.

Laud K, El-Haig W, Yannuzzi LA.

Retin Cases Brief Rep. 2008 Winter;2(1):41-3. doi: 10.1097/01.ICB.0000258960.61050.42.

PMID:
25389615
19.

Cutaneous phenotype and MC1R variants as modifying factors for the development of melanoma in CDKN2A G101W mutation carriers from 4 countries.

Goldstein AM, Chaudru V, Ghiorzo P, Badenas C, Malvehy J, Pastorino L, Laud K, Hulley B, Avril MF, Puig-Butille JA, Miniere A, Marti R, Chompret A, Cuellar F, Kolm I, Mila M, Tucker MA, Demenais F, Bianchi-Scarra G, Puig S, de-Paillerets BB.

Int J Cancer. 2007 Aug 15;121(4):825-31.

20.

Autofluorescence imaging of optic pit maculopathy.

Laud K, Visaetsilpanonta S, Yannuzzi LA, Spaide RF.

Retina. 2007 Jan;27(1):116-9. No abstract available.

PMID:
17218928
21.

Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab.

Laud K, Spaide RF, Freund KB, Slakter J, Klancnik JM Jr.

Retina. 2006 Oct;26(8):960-3. No abstract available.

PMID:
17031300
22.

Silicone oil droplets following intravitreal injection.

Freund KB, Laud K, Eandi CM, Spaide RF.

Retina. 2006 Jul-Aug;26(6):701-3. No abstract available.

PMID:
16829818
23.

Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.

Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J, Fisher YL, Cooney MJ.

Retina. 2006 Apr;26(4):383-90.

PMID:
16603955
24.

Melanocortin-1 receptor (MC1R) gene variants and dysplastic nevi modify penetrance of CDKN2A mutations in French melanoma-prone pedigrees.

Chaudru V, Laud K, Avril MF, Minière A, Chompret A, Bressac-de Paillerets B, Demenais F.

Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2384-90.

25.

Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma.

Laud K, Marian C, Avril MF, Barrois M, Chompret A, Goldstein AM, Tucker MA, Clark PA, Peters G, Chaudru V, Demenais F, Spatz A, Smith MW, Lenoir GM, Bressac-de Paillerets B; French Hereditary Melanoma Study Group.

J Med Genet. 2006 Jan;43(1):39-47. Epub 2005 Jun 3.

26.

Search for germline alterations in CDKN2A/ARF and CDK4 of 42 Jewish melanoma families with or without neural system tumours.

Marian C, Scope A, Laud K, Friedman E, Pavlotsky F, Yakobson E, Bressac-de Paillerets B, Azizi E.

Br J Cancer. 2005 Jun 20;92(12):2278-85.

27.

CDKN2A as a uveal and cutaneous melanoma susceptibility gene.

Kannengiesser C, Avril MF, Spatz A, Laud K, Lenoir GM, Bressac-de-Paillerets B.

Genes Chromosomes Cancer. 2003 Nov;38(3):265-8.

PMID:
14506702
28.

BRAF as a melanoma susceptibility candidate gene?

Laud K, Kannengiesser C, Avril MF, Chompret A, Stoppa-Lyonnet D, Desjardins L, Eychene A, Demenais F, Lenoir GM, Bressac-de Paillerets B; French Herediatary Melanoma Study Group.

Cancer Res. 2003 Jun 15;63(12):3061-5.

29.

Mammary leptin synthesis, milk leptin and their putative physiological roles.

Bonnet M, Delavaud C, Laud K, Gourdou I, Leroux C, Djiane J, Chilliard Y.

Reprod Nutr Dev. 2002 Sep-Oct;42(5):399-413. Review.

PMID:
12537253
30.

Identification of leptin receptors in human breast cancer: functional activity in the T47-D breast cancer cell line.

Laud K, Gourdou I, Pessemesse L, Peyrat JP, Djiane J.

Mol Cell Endocrinol. 2002 Feb 25;188(1-2):219-26.

PMID:
11911959
31.

Expression of BRCA1 gene in ewe mammary epithelial cells during pregnancy: regulation by growth hormone and steroid hormones.

Laud K, Hornez L, Gourdou I, Belair L, Arnold A, Peyrat JP, Djiane J.

Eur J Endocrinol. 2001 Dec;145(6):763-70.

PMID:
11720902
32.

Characterization and modulation of a prolactin receptor mRNA isoform in normal and tumoral human breast tissues.

Laud K, Gourdou I, Belair L, Peyrat JP, Djiane J.

Int J Cancer. 2000 Mar 15;85(6):771-6.

33.

Increase in prolactin receptor (PRL-R) mRNA level in the mammary gland after hormonal induction of lactation in virgin ewes.

Cassy S, Charlier M, Bélair L, Guillomot M, Laud K, Djiane J.

Domest Anim Endocrinol. 2000 Jan;18(1):41-55.

PMID:
10701763
34.

Detection and regulation of leptin receptor mRNA in ovine mammary epithelial cells during pregnancy and lactation.

Laud K, Gourdou I, Bélair L, Keisler DH, Djiane J.

FEBS Lett. 1999 Dec 10;463(1-2):194-8.

35.

Cell cycle effects and control of gene expression by resveratrol in human breast carcinoma cell lines with different metastatic potentials.

Hsieh TC, Burfeind P, Laud K, Backer JM, Traganos F, Darzynkiewicz Z, Wu JM.

Int J Oncol. 1999 Aug;15(2):245-52.

PMID:
10402233

Supplemental Content

Support Center